NMN (Nicotinamide Mononucleotide)

Nicotinamide mononucleotide (NMN) is a naturally occurring nucleotide that acts as a direct precursor in the body's synthesis of NAD+. It has drawn substantial research and consumer interest as an oral supplement for metabolic health and age-related decline, and more recently as a subcutaneous injectable for those seeking to bypass gut metabolism. A handful of human trials have examined its effects on insulin sensitivity, vascular function, and physical performance, with mixed and generally modest results to date. It is one of the most widely marketed NAD+ precursors alongside nicotinamide riboside (NR), though the two are processed through different pathways. Long-term safety and optimal dosing in humans remain areas of active investigation. Reported benefits include studied for potential support of insulin sensitivity in early human trials, explored for vascular and cardiovascular metabolic markers, investigated for exercise-related endurance outcomes.

Reported ranges run 125-500 mg. A low protocol is 125 mg once daily, and a high protocol is 500 mg once daily. This is reference information, not a dosing recommendation.

Short plasma half-life, well under an hour; intracellular NAD+ elevation is more prolonged.. That is what sets the dosing frequency, and it is why the timing guidance is morning.

Subcutaneous: into fat, under the skin. Oral and sublingual capsules are the most common consumer form; subcutaneous injection is used in some protocols to bypass first-pass gut metabolism.

Continuous or 8-12 week blocks on, followed by 1-2 weeks off. Many users take NMN continuously; periodic breaks are sometimes suggested but are not established as necessary.

Reported side effects include generally reported as well tolerated at studied oral doses, mild nausea or gastrointestinal upset in some users, injection-site reactions with subcutaneous administration, long-term human safety data remain limited. Evidence level for this compound is moderate evidence.